108 related articles for article (PubMed ID: 7022295)
1. Cyclic combination chemotherapy for metastatic breast cancer: comparison of two CMF schedules.
Biran S; Brufman G
Oncology; 1981; 38(5):257-9. PubMed ID: 7022295
[TBL] [Abstract][Full Text] [Related]
2. Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study.
Ackland SP; Anton A; Breitbach GP; Colajori E; Tursi JM; Delfino C; Efremidis A; Ezzat A; Fittipaldo A; Kolaric K; Lopez M; Viaro D;
J Clin Oncol; 2001 Feb; 19(4):943-53. PubMed ID: 11181656
[TBL] [Abstract][Full Text] [Related]
3. [Clinical evaluation of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) on advanced and recurrent breast cancer. Clinical study group of CMF for breast cancer in Japan].
Nomura Y; Tominaga T; Adachi I; Koyama H; Fukami A
Gan To Kagaku Ryoho; 1994 Sep; 21(12):1949-56. PubMed ID: 8085846
[TBL] [Abstract][Full Text] [Related]
4. Low dose chemotherapy of metastatic breast cancer with cyclophosphamide, adriamycin, methotrexate, 5-fluorouracil (CAMF) versus sequential cyclophosphamide, methotrexate, 5-fluorouracil (CMF) and adriamycin.
Creech RH; Catalano RB; Harris DT; Engstrom PF; Grotzinger PJ
Cancer; 1979 Jan; 43(1):51-9. PubMed ID: 367574
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant chemotherapy in operable breast cancer: cyclophosphamide, methotrexate, and fluorouracil versus chlorambucil, methotrexate, and fluorouracil--11-year results of Swiss Group for Clinical Cancer Research trial SAKK 27/82.
Senn HJ; Maibach R; Castiglione M; Jungi WF; Cavalli F; Leyvraz S; Obrecht JP; Schildknecht O; Siegenthaler P
J Clin Oncol; 1997 Jul; 15(7):2502-9. PubMed ID: 9215818
[TBL] [Abstract][Full Text] [Related]
6. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
[TBL] [Abstract][Full Text] [Related]
7. Correlation of estrogen receptors and response to chemotherapy of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in advanced breast cancer.
Chang JC; Wergowske G
Cancer; 1981 Dec; 48(11):2503-6. PubMed ID: 7296498
[TBL] [Abstract][Full Text] [Related]
8. Sequential administration of cyclophosphamide, methotrexate, 5-fluorouracil, and folinic acid as salvage treatment in metastatic breast cancer.
Pronzato P; Amoroso D; Ardizzoni A; Bertelli G; Canobbio L; Conte PF; Cusimano MP; Fusco V; Gulisano M; Lionetto R
Am J Clin Oncol; 1987 Oct; 10(5):404-6. PubMed ID: 3310605
[TBL] [Abstract][Full Text] [Related]
9. A new six-drug antiblastic regimen (R 14) at low doses (micropolychemotherapy) compared to CMF in the treatment of metastatic breast cancer: phase III study.
Pannuti F; Iafelice G; Martoni A; Fruet F; Angelelli B; Casadei M
Chemioterapia; 1984 Aug; 3(4):216-9. PubMed ID: 6398121
[TBL] [Abstract][Full Text] [Related]
10. MMM (mitomycin/mitoxantrone/methotrexate): an effective new regimen in the treatment of metastatic breast cancer.
Smith IE; Powles TJ
Oncology; 1993 Apr; 50 Suppl 1():9-15. PubMed ID: 8483562
[TBL] [Abstract][Full Text] [Related]
11. Anticipatory vomiting in women receiving cyclophosphamide, methotrexate, and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma.
Wilcox PM; Fetting JH; Nettesheim KM; Abeloff MD
Cancer Treat Rep; 1982 Aug; 66(8):1601-4. PubMed ID: 7049385
[TBL] [Abstract][Full Text] [Related]
12. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil.
Fisher B; Dignam J; Mamounas EP; Costantino JP; Wickerham DL; Redmond C; Wolmark N; Dimitrov NV; Bowman DM; Glass AG; Atkins JN; Abramson N; Sutherland CM; Aron BS; Margolese RG
J Clin Oncol; 1996 Jul; 14(7):1982-92. PubMed ID: 8683228
[TBL] [Abstract][Full Text] [Related]
13. Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. boccardo@hp380.ist.unige.it.
Boccardo F; Rubagotti A; Amoroso D; Mesiti M; Romeo D; Sismondi P; Giai M; Genta F; Pacini P; Distante V; Bolognesi A; Aldrighetti D; Farris A
J Clin Oncol; 2000 Jul; 18(14):2718-27. PubMed ID: 10894871
[TBL] [Abstract][Full Text] [Related]
14. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.
Levine MN; Bramwell VH; Pritchard KI; Norris BD; Shepherd LE; Abu-Zahra H; Findlay B; Warr D; Bowman D; Myles J; Arnold A; Vandenberg T; MacKenzie R; Robert J; Ottaway J; Burnell M; Williams CK; Tu D
J Clin Oncol; 1998 Aug; 16(8):2651-8. PubMed ID: 9704715
[TBL] [Abstract][Full Text] [Related]
15. CCNU, melphalan, methotrexate, and prednisone (CAMP) versus cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in the treatment of advanced breast cancer in postmenopausal women.
Salimtschik M; Snel S; Havsteen H; Dombernowsky P; Mouridsen HT
Cancer Treat Rep; 1980; 64(4-5):635-7. PubMed ID: 7000346
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemoendocrine therapy in postmenopausal breast cancer: cyclophosphamide, methotrexate, and fluorouracil dose and schedule may make a difference. International Breast Cancer Study Group.
Goldhirsch A; Coates AS; Colleoni M; Castiglione-Gertsch M; Gelber RD
J Clin Oncol; 1998 Apr; 16(4):1358-62. PubMed ID: 9552037
[TBL] [Abstract][Full Text] [Related]
17. Sequential administration of doxorubicin and paclitaxel followed by cyclophosphamide, methotrexate and 5-fluorouracil combination (CMF) in women with metastatic breast cancer.
Papadimitriou CA; Dimopoulos MA; Ampela C; Louvrou-Fertaki A; Anagnostopoulos A; Athanassiades P; Stamatelopoulos S; Keramopoulos A
Oncology; 1998; 55(6):533-7. PubMed ID: 9778619
[TBL] [Abstract][Full Text] [Related]
18. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15.
Fisher B; Brown AM; Dimitrov NV; Poisson R; Redmond C; Margolese RG; Bowman D; Wolmark N; Wickerham DL; Kardinal CG
J Clin Oncol; 1990 Sep; 8(9):1483-96. PubMed ID: 2202791
[TBL] [Abstract][Full Text] [Related]
19. [Primary chemotherapy of metastatic breast carcinoma with bendamustine hydrochloride, methotrexate and fluorouracil versus cyclophosphamide, methotrexate and fluorouracil].
Ruffert K
Zentralbl Chir; 1998; 123 Suppl 5():156-8. PubMed ID: 10063603
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant chemotherapy with cyclophosphamide, mitoxantrone, and 5-fluorouracil in locally advanced breast cancer.
Erol K; Baltali E; Altundag K; Guler N; Ozisik Y; Onat DA; Sayek I; Cengiz M; Atahan L; Tekuzman G
Onkologie; 2005 Feb; 28(2):81-5. PubMed ID: 15662111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
